RECIST: Harmonizing response criteria in oncology

Anas Younes, MD, from the Memorial Sloane-Kettering Cancer Center, New York, NY, talks to us about harmonising the criteria for evaluating response in lymphoma clinical trials with the Response Evaluation Criteria in Solid Tumors (RECIST). A group of international lymphoma experts from academic centers and pharmaceutical companies, radiologists, and statisticians have collaborated to harmonize lymphoma response criteria with RECIST, hypothesizing that single-dimension measurement may be used to assess response with results similar to those with standard criteria, as detailed by Prof. Younes. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.